MK-1496

DB12763InvestigationalSmall molecule

MK-1496 has been used in trials studying the treatment of Neoplasms and Malignant.

Mechanism: Pharmacologically active on Serine/threonine-protein kinase PLK1
Curator reviewed
Formula / weight: C₁₄H₂₄N₂O · 236.359 g/mol (avg)
Code names: MK-1496

Resolves to

Compound

Structure

InChIKeyKUHBBYPXWKYKKR-GXFFZTMASA-NSMILESC[C@H](N)C1=CC=C(C=C1)[C@H](O)CNC(C)(C)C

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with MK-1496, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.